<div class="container">

<table style="width: 100%;"><tr>
<td>ACTG175</td>
<td style="text-align: right;">R Documentation</td>
</tr></table>
<h2>AIDS Clinical Trials Group Study 175</h2>

<h3>Description</h3>

<p>ACTG 175 was a randomized clinical trial to compare monotherapy with zidovudine or didanosine with 
combination therapy with zidovudine and didanosine or zidovudine and zalcitabine in adults infected with the human 
immunodeficiency virus type I whose CD4 T cell counts were between 200 and 500 per cubic millimeter.</p>


<h3>Usage</h3>

<pre><code class="language-R">data(ACTG175)</code></pre>


<h3>Format</h3>

<p>A data frame with 2139 observations on the following 27 variables:
</p>

<dl>
<dt><code>pidnum</code></dt>
<dd>
<p>patient's ID number</p>
</dd>
<dt><code>age</code></dt>
<dd>
<p>age in years at baseline</p>
</dd>
<dt><code>wtkg</code></dt>
<dd>
<p>weight in kg at baseline</p>
</dd>
<dt><code>hemo</code></dt>
<dd>
<p>hemophilia (0=no, 1=yes)</p>
</dd>
<dt><code>homo</code></dt>
<dd>
<p>homosexual activity (0=no, 1=yes)</p>
</dd>
<dt><code>drugs</code></dt>
<dd>
<p>history of intravenous drug use (0=no, 1=yes)</p>
</dd>
<dt><code>karnof</code></dt>
<dd>
<p>Karnofsky score (on a scale of 0-100)</p>
</dd>
<dt><code>oprior</code></dt>
<dd>
<p>non-zidovudine antiretroviral therapy prior to initiation of study treatment (0=no, 1=yes)</p>
</dd>
<dt><code>z30</code></dt>
<dd>
<p>zidovudine use in the 30 days prior to treatment initiation (0=no, 1=yes)</p>
</dd>
<dt><code>zprior</code></dt>
<dd>
<p>zidovudine use prior to treatment initiation (0=no, 1=yes)</p>
</dd>
<dt><code>preanti</code></dt>
<dd>
<p>number of days of previously received antiretroviral therapy</p>
</dd>
<dt><code>race</code></dt>
<dd>
<p>race (0=white, 1=non-white)</p>
</dd>
<dt><code>gender</code></dt>
<dd>
<p>gender (0=female, 1=male)</p>
</dd>
<dt><code>str2</code></dt>
<dd>
<p>antiretroviral history (0=naive, 1=experienced)</p>
</dd>
<dt><code>strat</code></dt>
<dd>
<p>antiretroviral history stratification (1='antiretroviral naive', 2='&gt; 1 but <code class="reqn">\leq</code> 52 weeks of prior
antiretroviral therapy', 3='&gt; 52 weeks')</p>
</dd>
<dt><code>symptom</code></dt>
<dd>
<p>symptomatic indicator (0=asymptomatic, 1=symptomatic)</p>
</dd>
<dt><code>treat</code></dt>
<dd>
<p>treatment indicator (0=zidovudine only, 1=other therapies)</p>
</dd>
<dt><code>offtrt</code></dt>
<dd>
<p>indicator of off-treatment before 96<code class="reqn">\pm</code>5 weeks (0=no,1=yes)</p>
</dd>
<dt><code>cd40</code></dt>
<dd>
<p>CD4 T cell count at baseline</p>
</dd>
<dt><code>cd420</code></dt>
<dd>
<p>CD4 T cell count at 20<code class="reqn">\pm</code>5 weeks</p>
</dd>
<dt><code>cd496</code></dt>
<dd>
<p>CD4 T cell count at 96<code class="reqn">\pm</code>5 weeks (=<code>NA</code> if missing)</p>
</dd>
<dt><code>r</code></dt>
<dd>
<p>missing CD4 T cell count at 96<code class="reqn">\pm</code>5 weeks (0=missing, 1=observed)</p>
</dd>
<dt><code>cd80</code></dt>
<dd>
<p>CD8 T cell count at baseline</p>
</dd>
<dt><code>cd820</code></dt>
<dd>
<p>CD8 T cell count at 20<code class="reqn">\pm</code>5 weeks</p>
</dd>
<dt><code>cens</code></dt>
<dd>
<p>indicator of observing the event in <code>days</code></p>
</dd>
<dt><code>days</code></dt>
<dd>
<p>number of days until the first occurrence of: (i) a decline in CD4 T cell count of at least 50
(ii) an event indicating progression to AIDS, or (iii) death.</p>
</dd>
<dt><code>arms</code></dt>
<dd>
<p>treatment arm (0=zidovudine, 1=zidovudine and didanosine, 2=zidovudine and zalcitabine, 
3=didanosine).</p>
</dd>
</dl>
<h3>Details</h3>

<p>The variable <code>days</code> contains right-censored time-to-event observations. The data set includes 
the following post-randomization covariates: CD4 and CD8 T cell count at 20<code class="reqn">\pm</code>5 
weeks and the indicator of whether or not the patient was taken off-treatment before 96<code class="reqn">\pm</code>5 weeks.</p>


<h3>References</h3>

<p>Hammer SM, et al. (1996), "A trial comparing nucleoside monotherapy with combination therapy in 
HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter.", <em>New England Journal of Medicine</em>, 
335:1081â€“1090.</p>


</div>